Maria, a lymphoma patient from Russia, returned to Beijing for her second round of treatment at GoBroad Healthcare Group. For her, this was not merely a medical trip across borders—it was a vital journey toward reclaiming her health and restoring her quality of life. Her attending physician, Dr. Zhang Yajing, a hematology and oncology expert, recounted the treatment process in detail—beginning with the initial remote consultation, the reversal of her critical condition, and leading to her current stable status as she prepares for discharge. Every step was decisive.

First Visit to China: Critical Condition with Rapidly Worsening Disease

Maria first arrived in Beijing in June. At that time, her condition was extremely severe. Dr. Zhang vividly remembers her status during the initial overseas video consultation:

“She was in grave danger, with fevers soaring to 43–44°C, levels rarely seen in clinical practice.”

Even more challenging was the aggressive behavior of the tumor—it rebounded quickly after initial treatment, despite her blood counts not yet recovering, and had already involved the central nervous system, liver, and other organs. From a medical perspective, she was on the edge of high-risk deterioration.

Young and determined to maintain not only survival but a high quality of life, Maria received a comprehensive treatment plan centered on multi-target CAR-T therapy. Her first treatment adopted CD19 + CD22 dual-target CAR-T, after which her condition significantly improved. The previously aggressive manifestations—including CNS and liver involvement—were gradually brought under control.

Second Visit: Fighting for a More Durable Remission

Although the first treatment produced encouraging results, Maria’s disease carried a high risk of relapse. The original plan recommended hematopoietic stem cell transplantation once remission was achieved. However, after returning home, local specialists evaluated that she might not tolerate transplant conditioning.

Dr. Zhang’s team therefore redesigned a new strategy: sequential CAR-T consolidation, this time selecting CD20 + CD79b dual-target CAR-T based on her tumor’s antigen expression profile.

“Sequential therapy is not a simple repeat,” Dr. Zhang explained. “It is a comprehensive, personalized decision built on the tumor’s biology and her initial treatment response, aiming for a deeper and more durable remission.”

Her second treatment has now progressed smoothly. She is expected to be discharged with stable condition and without recurrence of the previously alarming aggressive features.

Comprehensive Lifecycle Management: Beyond Treatment, Ensuring Long-Term Confidence

Maria values quality of life and demonstrates strong medical understanding and cooperation, allowing the team to maintain clear communication and high-efficiency decision-making. To ensure long-term management, Dr. Zhang’s team developed a full lifecycle follow-up plan—including structured, more frequent follow-ups during the first two years, monthly testing schedules, and one-on-one online consultations after key evaluations to adjust treatment in a timely manner.

Maria expressed strong confidence in the plan and high satisfaction with the treatment outcomes and care experience.
From her initial crisis to her second cross-border visit, from precision treatment planning to her upcoming recovery and discharge, Maria’s journey embodies not only advanced medical decision-making but also GoBroad’s core philosophy:
Responsibility for life, and responsibility for the future.